CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,157 | -12.9% | 2,731 | +7.4% | 0.00% | 0.0% |
| Q2 2023 | $86,284 | -5.7% | 2,543 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $91,497 | -27.5% | 2,543 | -10.2% | 0.01% | -16.7% |
| Q4 2022 | $126,267 | +49.9% | 2,833 | -5.4% | 0.01% | +50.0% |
| Q3 2022 | $84,218 | +4.3% | 2,996 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $80,772 | -20.8% | 2,996 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $102,044 | -78.3% | 2,996 | -75.3% | 0.00% | -33.3% |
| Q4 2021 | $469,399 | -28.4% | 12,148 | 0.0% | 0.01% | -40.0% |
| Q3 2021 | $655,871 | +76.6% | 12,148 | +9.4% | 0.01% | +100.0% |
| Q2 2021 | $371,418 | – | 11,107 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |